Lataa...
Toxicity management for patients receiving novel T-cell engaging therapies
PURPOSE OF REVIEW: Recent clinical trials using T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cells, as well as engineered T cells that express targeting and activation molecules known as chimeric antigen receptors, have demonstrated powerful proof of c...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4198063/ https://ncbi.nlm.nih.gov/pubmed/24362408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOP.0000000000000043 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|